U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561554) titled 'Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation' on March 23.

Brief Summary: This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.

Study Start Date: March 06

Study Type: INTERVENTIONAL

Condition: Solid Tumors (Phase 1)

Intervention: DRUG: HSK42360-Na

Oral administration

Recruitment Status: RECRUITING

Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Disclaimer: Curated by HT Syndication....